Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

Roche

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT02954471

ML29903

Details and patient eligibility

About

This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian participants diagnosed with breast cancer between 2007 and 2013 and with available human epidermal growth factor receptor 2 (HER2) testing. Data on survival will be collected through 2015.

Enrollment: 351 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Initially diagnosed with breast cancer
• Has a proven result of HER2 testing by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) or any other in situ hybridization (ISH) method
• Alive or not alive

Exclusion criteria

• Inconclusive, equivocal or unavailable result of HER2/neu overexpression by IHC and FISH

Trial design

351 participants in 1 patient group

Participants With Breast Cancer

Description:

This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.